Skip to content

Safety and Efficacy of Two Oral Tinidazole Regimens for Refractory Trichomonas Vaginitis

Oral Tinidazole Treatment of Refractory Trichomonas Vaginitis

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05383521
Enrollment
20
Registered
2022-05-20
Start date
2025-12-01
Completion date
2025-12-30
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trichomonas Vaginitis

Keywords

Refractory Trichomonas Vaginitis, Tinidazole

Brief summary

We compare two oral tinidazole regimens for refractory trichomonas vaginitis.

Detailed description

Refractory trichomonas vaginitis has become a clinical problem, which has a direct impact on the health and life of patients. Refractory trichomonas vaginitis is mainly caused by drug resistance of trichomonas. Drug resistant trichomonas has appeared China. Increasing the dosage of anti trichomonal drugs is the main treatment method at present. The aim of this study was to evaluate the efficacy and safety of two oral tinidazole regimens for refractory trichomonas vaginitis.

Interventions

DRUGTinidazole 56

Tinidazole , 2g, twice daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.

DRUGTinidazole 42

Tinidazole , 1g, three times daily for 14 days. At the same time, metronidazole, 400 mg, once a day, vaginal administration, 14 days.

Sponsors

Shangrong Fan
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

For patients who failed to conventional treatment (recommended by the guidelines including tinidazole, 2g once daily for 5-7 days), the following regimens were selected: Tinidazole , 2g twice daily for 14 days. At the same time, metronidazole, 400 mg, daily, vaginal administration for 14 days. Tinidazole , 1g three times daily for 14 days. At the same time, metronidazole, 400 mg, daily, vaginal administration for 14 days.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Women be at least 18 years of age * Failure of conventional treatment (recommended by guidelines including tinidazole, 2g once daily for 5-7 days)

Exclusion criteria

* Allergy to metronidazole or tinidazol * Pregnant or nursing * HIV or other chronic disease

Design outcomes

Primary

MeasureTime frameDescription
Cure rate of refractory trichomoniasis24 weeksEvaluate the efficacy of oral tinidazole tablets in the treatment of refractory trichomoniasis.Diagnosis of vaginal trichomoniasis is performed by microscopy of vaginal secretions. Cure or failure was based on positive or negative T. vaginalis on vaginal secretions by microscopy examination.

Secondary

MeasureTime frameDescription
Safety of tinidazole tablets24 weeksNumber of participants with treatment-related adverse events as assessed by CTCAE v4.0. Test of blood routine,liver function, kidney function ,and urine routine will be done before treatment.The same test will be were reviewed within 1 week after treatment.

Countries

China

Contacts

Primary ContactYiheng Liang, M.D.
13510331823@163.com86-755-83923333
Backup ContactPing Liu, M.D.
253783006@qq.com86-755-83923333

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026